Companies / Neurogene Inc.

Neurogene Inc.

Nasdaq: NGNECIK 1404644NEW YORK, NY

Financials ยท FY2025

Revenue$0
Net income$-90.35M
Total debtโ€”
Cash$112.48M
Diluted EPS$-4.24
Shares outstanding20.0M

Ownership

20.0M shares outstanding ยท as of Aug 7, 2026
7.3%Insiders
Ownership
Insiders7.30%1,460,019
Institutions85.51%17,110,859
Public float7.20%1,440,504

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insider% of sharesShares
McMinn RachelCEOChief Executive Officer ยท Director
6.72%1,344,307
Cvijic Christine MikailPresident and CFO
0.52%103,240
Cobb StuartFormerChief Scientific Officer
0.15%30,497
Jordan JulieChief Medical Officer
0.06%12,472
Baffi RobertDirector
โ€”โ€”
โ€”โ€”
โ€”โ€”
โ€”โ€”
Woods KeithDirector
โ€”โ€”

Institutional holders 98

View all โ†’
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ฮ”Position afterImpact
Feb 27, 2026Cvijic Christine Mikail
Executive
SellCommon Stock$120.5K-5K
-4.19%
109,843
0.55% of shares
medium
Mar 13, 2026Cobb Stuart
Executive
SellCommon Stock$81.5K-4K
-10.70%
33,303
0.17% of shares
low
Mar 26, 2026McMinn Rachel
CEO
SellCommon Stock$74.0K-3K
-0.25%
1,344,307
6.72% of shares
low
Mar 13, 2026Cobb Stuart
Executive
SellCommon Stock$56.7K-3K
-7.98%
30,645
0.15% of shares
low
Mar 26, 2026Cvijic Christine Mikail
Executive
SellCommon Stock$55.3K-3K
-2.42%
103,240
0.52% of shares
low
Mar 13, 2026Cvijic Christine Mikail
Executive
SellCommon Stock$48.7K-2K
-2.17%
107,456
0.54% of shares
low
Mar 13, 2026Cvijic Christine Mikail
Executive
SellCommon Stock$29.6K-1K
-1.30%
106,061
0.53% of shares
low
Mar 26, 2026Jordan Julie
Executive
SellCommon Stock$18.1K-828
-6.23%
12,472
0.06% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Redmile Group, LLCPassive13G/Aโ€”โ€”โ€”

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
NGNECommon StockEquity64135M105BBG005Y0QDK1